Login to Your Account

Clinic Roundup

Wednesday, May 15, 2013
• Rib-X Pharmaceuticals Inc., of New Haven, Conn., said it started a Phase III trial testing delafloxacin, a fluoroquinolone antibiotic, in patients with acute bacterial skin and skin structure infections.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription